QIAGEN Quick Ratio 2010-2022 | QGEN

Historical quick ratio values for QIAGEN (QGEN) over the last 10 years.
QIAGEN Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2022-09-30 $2.43B $1.50B 1.62
2022-06-30 $1.82B $0.96B 1.89
2022-03-31 $1.78B $0.96B 1.86
2021-12-31 $1.78B $1.52B 1.17
2021-09-30 $1.69B $1.07B 1.58
2021-06-30 $1.46B $0.50B 2.90
2021-03-31 $1.35B $0.50B 2.70
2020-12-31 $1.33B $0.57B 2.33
2020-09-30 $1.33B $1.09B 1.22
2020-06-30 $1.43B $0.96B 1.50
2020-03-31 $1.41B $1.00B 1.42
2019-12-31 $1.40B $0.95B 1.47
2019-09-30 $1.37B $0.63B 2.18
2019-06-30 $1.45B $0.91B 1.59
2019-03-31 $1.43B $0.94B 1.52
2018-12-31 $1.99B $0.97B 2.05
2018-09-30 $1.71B $1.37B 1.25
2018-06-30 $1.53B $0.94B 1.63
2018-03-31 $1.59B $0.82B 1.94
2017-12-31 $1.49B $0.33B 4.59
2017-09-30 $1.41B $0.30B 4.78
2017-06-30 $1.00B $0.30B 3.34
2017-03-31 $0.62B $0.27B 2.26
2016-12-31 $0.90B $0.31B 2.92
2016-09-30 $0.82B $0.25B 3.27
2016-06-30 $0.76B $0.25B 3.06
2016-03-31 $0.81B $0.25B 3.31
2015-12-31 $0.83B $0.27B 3.07
2015-09-30 $0.84B $0.28B 3.04
2015-06-30 $0.79B $0.27B 2.98
2015-03-31 $0.82B $0.33B 2.47
2014-12-31 $1.02B $0.43B 2.36
2014-09-30 $1.14B $0.44B 2.61
2014-06-30 $1.07B $0.30B 3.60
2014-03-31 $1.08B $0.31B 3.45
2013-12-31 $0.79B $0.34B 2.35
2013-09-30 $0.73B $0.30B 2.41
2013-06-30 $0.77B $0.30B 2.59
2013-03-31 $0.85B $0.27B 3.17
2012-12-31 $0.86B $0.27B 3.21
2012-09-30 $0.66B $0.54B 1.22
2012-06-30 $0.60B $0.51B 1.18
2012-03-31 $0.63B $0.45B 1.38
2011-12-31 $0.61B $0.45B 1.36
2011-09-30 $0.83B $0.65B 1.28
2011-06-30 $1.27B $0.37B 3.47
2011-03-31 $1.26B $0.38B 3.35
2010-12-31 $1.24B $0.39B 3.19
2010-09-30 $1.22B $0.40B 3.09
2010-06-30 $1.24B $0.32B 3.84
2010-03-31 $1.21B $0.34B 3.57
2009-12-31 $1.20B $0.38B 3.20
2009-09-30 $1.24B $0.38B 3.29
2009-06-30 $0.67B $0.26B 2.52
2009-03-31 $0.60B $0.22B 2.68
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.333B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00